Avalo Therapeutics (NASDAQ:AVTX) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.
Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction. These clinical and preclinical assets are supported by a broader research portfolio exploring additional targets in inflammation, tissue remodeling and metabolic regulation. Avalo conducts in-house research at its headquarters in Redwood City, California, and collaborates with academic and industry partners across North America and Europe.
Founded in 2014, Avalo Therapeutics has assembled a management team with deep expertise in drug discovery, clinical development and commercialization. The leadership includes executives and scientists who have held senior roles at leading pharmaceutical and biotechnology firms, providing strategic guidance and operational experience as the company advances its pipeline. Avalo’s governance structure and advisory board further support rigorous scientific evaluation and cultural alignment with industry best practices.
With its integrated research capabilities, external partnerships and a focused pipeline of innovative candidates, Avalo Therapeutics aims to advance multiple programs toward late-stage clinical trials and ultimately deliver new treatment options for patients suffering from chronic cardiometabolic and inflammatory disorders.
